| Heather Norton, RPH | |
|
9350 Marshall Dr, Lenexa, KS 66215-3845 | |
| (913) 227-3702 | |
| (913) 227-3722 |
| Full Name | Heather Norton |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 9350 Marshall Dr, Lenexa, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477838605 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 11978 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Heather Norton, RPH 9350 Marshall Dr, Lenexa, KS 66215-3845 Ph: (913) 227-3702 | Heather Norton, RPH 9350 Marshall Dr, Lenexa, KS 66215-3845 Ph: (913) 227-3702 |
News Archive
PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB).
The world is in danger of missing targets for providing clean water and sanitation unless there is a dramatic increase in the pace of work and investment between now and 2015, according to a new report from the World Health Organization (WHO) and UNICEF.
Novozymes Biopharma has entered a new collaborative research agreement with one of the world's top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.
The recent CDC report on new HIV infections "underscore[s] ... the inexorable movement of the HIV/AIDS epidemic into black and other minority communities and the failure of government at all levels to respond to that change," C. Virginia Fields, president and CEO of the National Black Leadership Commission on AIDS, writes in a New York Daily News opinion piece (Fields, New York Daily News, 8/31).
Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
Jacob Thomas Stolz, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15100 W 87th Street Pkwy, Lenexa, KS 66219 Phone: 913-438-5172 | |
Katy Dolinar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 13400 W 87th Street Pkwy, Lenexa, KS 66215 Phone: 913-438-6651 | |
Christopher Shane Slifer, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11131 W 79th St, Lenexa, KS 66214 Phone: 913-234-4664 Fax: 913-234-4665 | |
Jill Ann Ottinger, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11131 W 79th St, Lenexa, KS 66214 Phone: 913-234-4664 | |
Jerald E. Bowmer, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 17301 W 84th Ter, Lenexa, KS 66219 Phone: 913-530-1493 Fax: 913-599-5435 | |
Ms. Elaine Carol Clancy, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11162 Renner Blvd, Lenexa, KS 66219 Phone: 800-360-0520 | |
Jonathan Fernandez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10050 Woodland Dr, Lenexa, KS 66220 Phone: 913-397-0906 Fax: 913-397-0332 |